Investments in Unconsolidated VIEs

6 Months Ended

Jun. 30, 2020

Equity Method Investments and Joint Ventures [Abstract]

Investments in Unconsolidated VIEs

Investments in Unconsolidated VIEs

In April 2020, the Company entered into a Development and Option Agreement (Development Agreement) with Navitor Pharmaceuticals, Inc. (Navitor). The Company can terminate the Development Agreement upon 30 days’ notice.

Under the terms of the Development Agreement, the Company and Navitor will jointly conduct a Phase II clinical program for NV-5138 (SPN-820) for treatment-resistant depression. The Company will bear all development costs incurred by either party up to a maximum of $50 million for Phase I and Phase II development, in addition to the costs that the Company will incur for other research and development support activities. There are certain additional payment amounts which could be incurred by the Company that are contingent upon Navitor achieving defined development milestones. The Company has an option to acquire or license NV-5138 (SPN-820), for which additional payments would be required. The Company paid Navitor a one time, nonrefundable, and non-creditable fee of $10 million for this option to acquire or license NV-5138 (SPN-820). This cost is included in Research and development expense in the condensed consolidated statement of earnings for the three and six months ended June 30, 2020.

In addition to entering into the Development Agreement, the Company acquired Series D Preferred Shares of Navitor for $15 million, representing approximately a 13% ownership position in Navitor. The Company has determined that Navitor is a VIE. The Company has not consolidated this VIE because the Company lacks the power to direct the activities that most significantly impact Navitor’s economic performance and, therefore, have accounted for the investment under the cost method of accounting and included in Other assets in the condensed consolidated balance sheets.

As of June 30, 2020, the carrying value of our investment in Navitor was approximately $15 million. The maximum exposure to losses related to Navitor is limited to the $15 million carrying value of the investment, a maximum of approximately $50 million for Phase I and Phase II development of NV-5138 (SPN-820), and the cost of other development and formulation activities provided by the Company until the date of termination of the Development Agreement.

We have provided no financing to Navitor other than amounts required under the Development Agreement.